BXCL701

DRUG2 trials

Sponsors

Georgetown University, Eric Stephen Winer, MD

Conditions

Acute Myeloid LeukemiaMetastatic Pancreatic Ductal AdenocarcinomaMyelodysplastic Syndrome With Excess Blasts-2

Phase 1

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

RecruitingNCT05703542

Eric Stephen Winer, MDAcute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2

Start: 2023-02-02End: 2026-07-31Target: 24Updated: 2025-07-18

Phase 2

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruitingNCT05558982

Georgetown UniversityMetastatic Pancreatic Ductal Adenocarcinoma

Start: 2023-08-16End: 2027-09-01Updated: 2026-09-14

Related Papers

BXCL701 plus pembrolizumab in second-line advanced pancreatic ductal adenocarcinoma: Final outcomes of the EXPEL PANC trial.

Journal of Clinical Oncology2026-05-27

Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.

Journal of Clinical Oncology2024-06-054 citations

Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood2023-11-02

Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC).

Journal of Clinical Oncology2023-06-011 citations